Good Read!!Transaction with the Salzman Group On May 19, 2020, Claritas announced that it had signed a Letter of Intent dated May 12, 2020 (the “LOI”) to acquire Salzman Group, Inc. (“Salzman Group”), a privately held company located in West Tisbury, MA (the “Acquisition”). Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of use patents in approximately 40 countries, including the U.S., Australia, Brazil, China, Europe, India, Japan, Russia and South Korea.
Claritas has decided not to proceed with the acquisition of Salzman Group. Instead, the Company will proceed to develop R-107 for the treatment of coronavirus and COVID-19 infection under the Company’s exclusive world-wide license for the development and commercialization of R-107.